参考文献

1.Altintas A, Petek B, Isik N, et al. Clinical And Radiological Characteris tics Of Tumefactive Demyelinating Lesions: Follow-up Study. Multiple Sclerosis Journal, 2013, 19： 656-656.

2.Kim HJ, Lee SM, Kim HD, et al. Schilder’s disease in a young child with tumefactive demyelinating brain lesion.Neurology Asia, 2013, 18： 419-421.

3.Todd AH, Heidi NB, Ian JS, et al. Balo ́’s concentric sclerosis and tumefactive demyelination: A shared immunopathogenesis? Journal of the neurological sciences, 2015, 348： 279-81.

4.Siri A, Carra DC, Ayrignac X, et al. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. Journal of Neurology, 2015, 262： 1637-1645.

5.Mehler MF, Rabinowich L. Inflammatory myelinoclastic diffuse sclerosis(Schilder’s disease)： neuroradiologic findings. American Journal of Neuroradiology, 1989, 10： 176-180.

6.Poser CM, et al. SCHILDERS MYELINOCLASTIC DIFFUSE SCLEROSIS. Pediatrics, 1986, 77： 107-112.

7.Suzuki M, Kawasaki H, Masaki K, et al. An Autops y Case of the Marburg Variant of Multiple Scleros is(Acute Multiple Sclerosis). Internal Medicine, 2013, 52： 1825-1832.

8.Talab R, Kundrata Z. Marburg Variant Multiple Sclerosis. Neuroendocrinology Letters, 2011, 32： 415-420.

9.Turatti M, Gajofatto A, Rossi F, et al. Long survival and clinical stability in Marburg’s variant multiple sclerosis.Neurological Sciences, 2010, 31： 807-811.

10.Nozaki K, Abou-Fayssal N. High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report. Journal of the Neurological Sciences, 2010, 296： 121-123.

11.Bitsch A, Wegener C, da Costa C, et al. Lesion development in Marburg’s type of acute multiple sclerosis: from inflammation to demyelination. Multiple Sclerosis, 1999, 5： 138-146.

12.Balo J. Encephalitis periaxialis concentrica. Archives of Neurology and Psychiatry, 1928, 19： 242-264.

13.Ng SH, Ko SF, Cheung YC, et al. MRI features of Balo’s concentric sclerosis. British Journal of Radiology, 1999,72： 400-403.

14.Hardy TA, Miller DH. Balo’s concentric sclerosis. Lancet Neurology. 2014, 13： 740-746.

15.Karaarslan E, Altintas A, Senol U, et al. Balo’s concentric sclerosis: Clinical and radiologic featur es of five cases. American Journal of Neuroradiology, 2001, 22： 1362-1367.

16.Kishimoto R, Yabe I, Niino M et al. Balo’s concentric sclerosis-like lesion in the brainstem of a multiple sclerosis patient. Journal of Neurology, 2008, 255： 760-761.

17.Graber JJ, Kister I, Geyer H et al. Neuromyelitis Optica and Concentric Rings of Balo in the Brainstem. Archives of Neurology, 2009, 66： 274-275.

18.Chitnis T, Hollmann TJ. CADASIL mutation and Balo concentric s clerosis: A link between dem yelination and ischemia? Neurology, 2012, 78： 221-223.

19.Masdeu JC, Quinto C, Olivera C, et al. Open-ring imaging sign-Highly specific for atypical brain demyelination.Neurology, 2000, 54： 1427-1433.

20.Poser S, L ü er W, Bruhn H, et al. ACUTE DEMYELINATING DISEASE-CLASSIFICATION AND NONINVASIVE DIAGNOSIS. Acta NeurologicaScandinavica, 1992, 86： 579-585.

21.Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain, 2008, 131： 1759-1775.

22.Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions:follow-up study. Multiple Sclerosis Journal, 2011, 18： 1448-1453.

23.Wallner-Blazek M, Rovira A, Fillipp M, et al. Atypical idiopathic inflammatory demyelinating lesions:prognostic implications and relation to multiple sclerosis. Journal of Neurology, 2013, 260： 2016-2022.

24.Gnanapavan S, Jaunmuktane Z, Baruteau KP, et al. A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann’s syndrome. BMC Neuroloy. 2014, 14： 68.

25.Liu J, Qiao W, Zheng K, et al. Comparison of tumefactive demyelinating lesions and glioma by clinical presentations and neuroimaging studies. Zhonghua yi xue za zhi, 2014, 94： 3047-51.

26.Yao J, Huang D, Gui Q, et al. Clinical and radiological characteristics of 17 Chinese pati ents with pathology confirmed tumefactive demyelinating diseases: Follow-up study. Journal of the neurological sciences, 2015, 348：153-9.

27.Nagappa M, Taly AB, Sinha S, et al. Tumefactive demyelination: clinical, imaging and follow-up observations in thirty-nine patients. Acta Neurologica Scandinavica, 2013, 128： 39-47.

28.김호균. Relapsing and Progressive Tumefactive Demyelinating Form of Central Nervous System Involvement in a Patient with Progressive Systemic Sclerosis. Journal of The Korean Radiological Society, 2013, 68： 197-200.

29.de Medeiros FC, de Albuquerque LA, Pittella JE, et al. Open-Ring Enhancement in Pseudotumoral Multiple Sclerosis: Important Radiological Aspect. Case Reports in Neurologic Medicine. 2014, 2014： 951690.

30.Mabray MC, Cohen BA, Villanueva-Meyer JE. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. AJR American Journal of Roentgenology. 2015, 205： 1075-85.

31.Lu SS, Kim SJ, Kim N, et al. Histogram Analysis of Apparent Diffusion Coefficient Maps for Differentiating Primary CNS Lymphomas From Tumefactive Demyelinating Lesions. American Journal of Roentgenology, 2015,204： 827-834.

32.Essig M, Anzalone N, Combs SE, et al. MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice. AJNR American Journal of Neuroradiology. 2012, 33： 803-17.

33.Balos DR, Gavrilov S, Lavr S, et al. Proton magnetic resonance spectroscopy and apparent diffusion coefficient in evaluation of solid brain lesions. Vojnosanitetski Pregled, 2013, 70： 637-644.

34.Kebir S, Gaertner FC, Mueller M, et al. 18F-uoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report. Oncology Letters. 2016, 11：2195-2198.

35.Mertens K, Bolcaen J, Ham H, et al. The optimal timing for imaging brain tumours and other brain lesions with F-18-labelled fluoromethylcholine a dynamic positron emission tomography study. Nuclear Medicine Communications, 2012, 33： 954-959.

36.Ng S, Butzkueven H, Kalnins R, et al. Prolonged interval between s entinel pseudotumoral demyelination and development of primary CNS lymphoma. Journal of Clinical Neuroscience, 2007, 14： 1126-1129.

37.Kato Y, Hayashi T, Kawai-Masaoka A, et al. Primary Central Nervous System Cytotoxic T-cell Lymphoma Mimicking Demyelinating Disease. Internal Medicine. 2014, 53： 1197-1200.

38.Yamamoto J, Shimajiri S, Nakano Y, et al. Primary cent ral nervous system lymphoma with preceding spontaneous pseudotumoral demyelination in an immunocompetent adult patient: A case report and literature review. Oncology Letters. 2014, 7： 1835-1838.

39.Sega S, Horvat A, Popovic M. Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients-Report of two cases. Clinical Neurology and Neurosurgery, 2006, 108： 259-265.

40.Golombievski EE, McCoyd MA, Lee JM et al. Biopsy proven tumefactive multiple sclerosis with concomitant glioma: case report and review of the literature. Frontiers in Neurology, 2015, 6： 150.

41.Cunliffe CH, Fischer I, Monoky D, et al. Intracranial L esions Mimicking Neoplasms. Archives of Pathology &Laboratory Medicine, 2009, 133： 101-123.

42.Jacquerye P, Ossemann M, Laloux P et al. Acute fulminant multiple sclerosis and plasma exchange. European Neurology, 1999, 41： 174-175.

43.Weinshenker BG. Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. Journal of Clinical Apheresis, 1999, 14： 144-148.

44.Fan XW, Mahta A, De Jager PL, et al. Rituximab for tumefactive inflammatory demyelination: A case report.Clinical Neurology and Neurosurgery, 2012, 114： 1326-1328.

45.Sempere AP, Feliu-Rey E, Sanchez-Perez R, et al. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. Journal of Neurology Neurosurgery and Psychiatry, 2013, 84： 1338-1339.

46.Ragel BT, Fassett DR, Baringer JR, et al, Decompressive hemicraniectomy for tumefactive demyelination with transtentorial herniation: observation. Surgical Neurology, 2006, 65： 582-583.

47.Hardy TA, Chataway J. Tumefactive demyelination: an approach to diagnosis and management. Journal of Neurology Neurosurgery and Psychiatry, 2013, 84： 1047-1053.

48.Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod A case report and literature review.Neurology, 2013, 81： 1654-1658.

49.Zhang-Auberson L, Tumefactive lesions in multiple sclerosis: MRI findings from phase 2 and 3 clinical trials of fingolimod. European Journal of Neurology, 2015, 22： 666.

50.Bhargava A, Pujar GS, Banakar BF, et al. Recurrent tumefactive demyelination: An unusual presentation.Journal of Pediatric Neurosciences, 2015, 10： 55-57.

51.Jeong IH, Kim SH, Hyun JW, et al. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging,and follow-up observations. Journal of the Neurological Sciences, 2015, 358： 118-124.

52.Graber JJ, Kister I, Gruber MC. et al. Predictors of Multiple Sclerosis Following Clinically Isolated Syndrome with a Tumefactive Demyelinating Lesion. Neurology, 2009, 72： 78. loTlggffeWuvLERje8SndWKsoOGmktXEKPT5b0BJARzaEqvOoYaoYYrbeaWuYMPh